To start your customized experience click the start button
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
CURE Communications Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.


Edward McClain
Ed chronicles part II of his chronic lymphocytic leukemia (CLL) story from the third person.
Gina Columbus
In an interview with CURE, John C. Byrd discusses the efficacy of acalabrutinib and how it compares with Imbruvica.
Anita T. Shaffer
Less than two years after Imbruvica gained approval for patients with CLL, a second-generation agent has demonstrated a 95 percent response rate.
Beth Fand Incollingo
The results showed a two-year overall survival rate of 98 percent with Imbruvica.
William G. Wierda
CURE spoke with Wierda at the 2015 Chemotherapy Foundation Symposium, a meeting of over 1,000 oncologists and oncology professionals.
Andrew J. Roth
Though clinical work is ongoing and early, researchers are already considering how to manage potentially fatal neurotoxicities in patients treated with chimeric antigen receptor (CAR) T-cell therapy.
Silas Inman
A phase 3 study exploring Zydelig in combination with Treanda and Rituxan for patients with previously treated CLL has been stopped early following a positive interim analysis.
Ed chronicles his chronic lymphocytic leukemia (CLL) story from the third person.
Stacy Verner
By donating stem cells through Be The Match, healthy adults can save the lives of people with blood cancers.
Erik Ness
Watching, waiting and then choosing from a bevy of new treatments can be a good strategy for many with CLL.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment


Healthcare Professional

Not Applicable